Ferroportin in monocytes of hemodialysis patients and its associations with hepcidin, inflammation, markers of iron status and resistance to erythropoietin

Eleftheriadis, Theodoros; Pissas, Georgios; Remoundou, Maria; Filippidis, Georgios; Antoniadi, Georgia; Oustampasidou, Niki; Liakopoulos, Vassilios; Stefanidis, Ioannis

doi:10.1007/s11255-013-0497-9

Cited by 16 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its potential use in our patients needs to be explored. However, recent studies have shown that there was no correlation between hepcidin levels and other markers of iron stores and function, casting doubts on its potential usefulness in hemodialysis patients …”

Section: Discussionmentioning

confidence: 99%

“…However, recent studies have shown that there was no correlation between hepcidin levels and other markers of iron stores and function, casting doubts on its potential usefulness in hemodialysis patients. 31,[37][38][39] The safety of giving iron to patients with low TSAT and ferritin above 1200 µg/L in our or similar circumstances will need further evaluation. High ferritin has been linked to all-cause mortality.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia

Majoni

Ellis

Hall

et al. 2014

Hemodialysis International

View full text Add to dashboard Cite

Use of erythropoiesis-stimulating agents (ESAs) has improved the management of anemia in patients on maintenance hemodialysis (MHD). Iron deficiency and inflammation cause ESAs resistance and are both common among indigenous people of Northern Australia. As part of quality assurance in our Renal Anaemia Management program, we observed that there was use of higher doses of ESAs and adjuvant iron therapy in our MHD patients. This study aimed to explore the relationship among iron studies, inflammation, ESA responsiveness, and ESAs and iron requirements in indigenous patients on MHD from the Top End of Northern Australia. We performed a retrospective cohort analysis of anemia management in a cohort of our patients on MHD. We extracted data for 178 indigenous and 19 non-indigenous patients from 1 March 2009 to 28 February 2010 from the Renal Anaemia Management database, which collects data prospectively in MHD patients. Ninety-nine percent of the whole sample had a ferritin level above the international guidelines threshold of >500 µg/L. Indigenous patients had higher ferritin (1534 ± 245.5 µg/L vs. 1013 ± 323.3 µg/L, P = 0.002). C-reactive protein (CRP) was high in 56.9% of the total cohort. One hundred percent of those with normal CRP had high ferritin (>500 µg/L). C-reactive protein was higher in indigenous than in non-indigenous patients. Erythropoiesis-stimulating agents hyporesponsiveness was higher in indigenous patients (P < 0.0001). There was no significant difference in ESAs hyporesponsiveness among different levels of CRP (P = 0.116), ferritin (P = 0.408), and transferrin saturation (P = 0.503). Indigenous patients required higher total iron dose (2820.30 [2000-4350] vs. 2336.12 [1912-2900], P = 0.02). There was no significant relationship between the high ferritin and CRP. In indigenous dialysis patients, iron therapy and ESAs use are higher. The high iron use is due to a lack of published evidence to guide the administration of iron in patients with high ferritin. The high ferritin and ESAs resistance could not be fully explained by inflammation and need further evaluation. Further studies are required to determine the safe use of iron and management of ESAs resistance in our hemodialysis population.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia

Majoni

Ellis

Hall

et al. 2014

Hemodialysis International

View full text Add to dashboard Cite

show abstract

“…In a study by Eleftheriadis et al, 29 ESA resistance was found to be negatively correlated with ferritin, and transferrin saturation. However, in our study, ERI was not found to be associated with these iron parameters.…”

mentioning

confidence: 91%

C-reactive protein but not hepcidin, NGAL and transferrin determines the ESA resistance in hemodialysis patients

et al. 2015

View full text Add to dashboard Cite

“…On the other hand, Eleftheriadis et al , in a study performed in HD patients after a washout period from iron treatment indicated that serum hepcidin was related neither to serum iron, TSAT, EPO resistance index nor to IL‐6. In that study, serum hepcidin was not related even to the ferroportin expression in monocytes . Damien.…”

Section: Discussionmentioning

confidence: 73%

Relationship of serum haemojuvelin and hepcidin levels with iron level and erythropoietin requirement in prevalent hepatitis C virus positive haemodialysis patients

et al. 2018

View full text Add to dashboard Cite

show abstract

Ferroportin in monocytes of hemodialysis patients and its associations with hepcidin, inflammation, markers of iron status and resistance to erythropoietin

Abstract: Decreased ferroportin in monocytes of HD patients accompanies increased hepcidin, inflammation, decreased iron availability and is correlated with resistance to rHuEpo treatment.

Cited by 16 publications

References 22 publications

Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia

Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia

C-reactive protein but not hepcidin, NGAL and transferrin determines the ESA resistance in hemodialysis patients

Relationship of serum haemojuvelin and hepcidin levels with iron level and erythropoietin requirement in prevalent hepatitis C virus positive haemodialysis patients

Contact Info

Product

Resources

About